A higher rate of serious infections has also been observed in patients with RA treated with rituximab who received subsequent treatment with a TNF blocker.
Source: FDA drug label - adalimumab-aacf
3 interactions on record
A higher rate of serious infections has also been observed in patients with RA treated with rituximab who received subsequent treatment with a TNF blocker.
Source: FDA drug label - adalimumab-aacf
A higher rate of serious infections has also been observed in patients with RA treated with rituximab who received subsequent treatment with a TNF blocker.
Source: FDA drug label - adalimumab-adbm
A higher rate of serious infections has also been observed in patients with RA treated with rituximab who received subsequent treatment with a TNF blocker.
Source: FDA drug label - adalimumab-ryvk